Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Biogen 2.736, Incyte 1.674.
Biogen vs Incyte: Revenue Comparison
Biogen (BIIB) and Incyte (INCY) are peers in Healthcare. Biogen reported revenue of $2.7B as of Q2 2026, compared with $1.7B for Incyte. Biogen leads on revenue.
Biogen's gross margin is 56.9% versus 93.7% for Incyte. Biogen's net margin is 3.6% versus 35.0% for Incyte.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Biogen, Incyte.| Metric | Biogen | Incyte |
|---|---|---|
| Market Cap | - | - |
| Revenue | $2.74B | $1.67B |
| Cost of Revenue | $1.18B | $105.00M |
| Gross Profit | $1.56B | $1.57B |
| Operating Income | $318.00M | $698.00M |
| Net Income | $98.00M | $586.00M |
| R&D Expense | $496.00M | $517.00M |
| Earnings Per Share | $0.66 | $2.81 |
| Gross Margin | 56.9% | 93.7% |
| Operating Margin | 11.6% | 41.7% |
| Net Profit Margin | 3.6% | 35.0% |
| Free Cash Flow | $490.00M | $495.00M |
| Cumulative Free Cash Flow | $47.88B | $3.86B |
| Operating Cash Flow | $449.00M | $508.00M |
| Cash & Equivalents | $1.28B | $3.98B |